Phase 2Data readout

KER-065

Duchenne muscular dystrophy

KROSKeros Therapeutics

Expected catalystJune 30, 2027Company guidance: Jun 30, 2027

Catalyst overview

Event details

Drug or asset: KER-065
Development stage: Phase 2
Event type: Data readout
Indication: Duchenne muscular dystrophy

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for KER-065 in Duchenne muscular dystrophy. The expected timing is based on the latest available company guidance and may change.

Development notes

05/14/26:- PR No update. 08/03/26:- Ph2 initiated; initial data expected H1 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source